JAZZ PHARMACEUTICALS FRANCE

🇫🇷France

Country: 🇫🇷France

Ownership: -

Established: 2003-01-01

Employees: -

Market Cap: -

Website: https://www.jazzpharma.com/careers/open-positions/

Clinical Trials

A Patient-Centric, Prospective, Observational, Non-Interventional Switch Study of XYWAV in Narcolepsy

Completed

Conditions: Narcolepsy

Interventions: Drug: Transition from Xyrem to Xywav

First Posted Date: 2021-03-18

Last Posted Date: 2022-06-30

Lead Sponsor: Jazz Pharmaceuticals

Target Recruit Count: 110

Registration Number: NCT04803786

Locations: 🇺🇸
Jazz Pharmaceuticals Clinical Site, Palo Alto, California, United States

An Interventional Safety Switch Study (Segue Study) of XYWAV in Narcolepsy

Phase 4

Completed

Conditions: Narcolepsy

Interventions: Drug: JZP-258

First Posted Date: 2021-03-12

Last Posted Date: 2024-01-09

Lead Sponsor: Jazz Pharmaceuticals

Target Recruit Count: 62

Registration Number: NCT04794491

Locations: 🇺🇸
Clinical Research of Gastonia, Gastonia, North Carolina, United States
🇺🇸
Minnesota Lung Center, Edina, Minnesota, United States
🇺🇸
Sleep Disorders Center of Alabama, Birmingham, Alabama, United States

and more 25 locations

Trial to Investigate the Safety and Efficacy of Cannabidiol Oral Solution (GWP42003-P; CBD-OS) in Children and Adolescents With Autism Spectrum Disorder

Phase 2

Completed

Conditions: Autism Spectrum Disorder

Interventions: Drug: GWP42003-P
Drug: Placebo

First Posted Date: 2021-02-09

Last Posted Date: 2024-02-20

Lead Sponsor: Jazz Pharmaceuticals

Target Recruit Count: 108

Registration Number: NCT04745026

Locations: 🇺🇸
Seattle Children's Research Institute, Seattle, Washington, United States
🇺🇸
UCSD School of Medicine, La Jolla, California, United States
🇦🇺
Queensland Children's Hospital, South Brisbane, Australia

and more 20 locations

Trial to Evaluate the Effect of Nabiximols Oromucosal Spray on Clinical Measures of Spasticity in Participants With Multiple Sclerosis

Phase 3

Completed

Conditions: Spasticity in Participants With Multiple Sclerosis

Interventions: Drug: Placebo
Drug: Nabiximols

First Posted Date: 2020-12-08

Last Posted Date: 2023-07-20

Lead Sponsor: Jazz Pharmaceuticals

Target Recruit Count: 68

Registration Number: NCT04657666

Locations: 🇵🇱
Clinical Trial Site 2, Poznan, Wielkopolskie, Poland
🇵🇱
Clinical Trial Site, Zabrze, Poland
🇵🇱
Clinical Trial Site 3, Katowice, Slaskie, Poland

and more 1 locations

Study of the Safety and Efficacy of Nabiximols Oromucosal Spray Versus Placebo in Patients With Post-traumatic Stress Disorder

Phase 2

Withdrawn

Conditions: Post-Traumatic Stress Disorder

Interventions: Drug: Placebo
Drug: Nabiximols

First Posted Date: 2020-10-19

Last Posted Date: 2022-06-03

Lead Sponsor: Jazz Pharmaceuticals

Registration Number: NCT04592159

An Expanded Access Treatment Protocol of Zanidatamab (ZW25) in Patients With HER2-Positive Advanced Biliary Tract Cancer

Conditions: HER2-Positive Advanced Biliary Tract Cancer

First Posted Date: 2020-10-08

Last Posted Date: 2024-07-23

Lead Sponsor: Jazz Pharmaceuticals

Registration Number: NCT04578444

Locations: 🇫🇷
Jean Minjoz Hospital, Besançon, France
🇫🇷
Hopital Haut-Leveque - CHU Bordeaux, Pessac, France
🇫🇷
Gustave Roussy Cancer Center, Villejuif, France

and more 14 locations

Assessment of Adjunctive Cannabidiol Oral Solution (GWP42003-P) in Children With Tuberous Sclerosis Complex (TSC), Dravet Syndrome (DS), or Lennox-Gastaut Syndrome (LGS) Who Experience Inadequately-controlled Seizures

Phase 3

Recruiting

Conditions: Seizure in Participants With Dravet Syndrome
Seizure in Participants With Tuberous Sclerosis Complex
Seizure in Participants With Lennox-Gastaut Syndrome

Interventions: Drug: GWP42003-P

First Posted Date: 2020-07-24

Last Posted Date: 2024-12-09

Lead Sponsor: Jazz Pharmaceuticals

Target Recruit Count: 27

Registration Number: NCT04485104

Locations: 🇪🇸
Clinical Trial Site, Madrid, Spain

A Study of ZW25 (Zanidatamab) in Subjects With Advanced or Metastatic HER2-Amplified Biliary Tract Cancers

Phase 2

Completed

Conditions: HER2-amplified Biliary Tract Cancers

Interventions: Drug: ZW25 (Zanidatamab)

First Posted Date: 2020-07-10

Last Posted Date: 2024-08-21

Lead Sponsor: Jazz Pharmaceuticals

Target Recruit Count: 87

Registration Number: NCT04466891

Locations: 🇺🇸
University of Maryland Greenebaum Cancer Center, Baltimore, Maryland, United States
🇺🇸
Winship Cancer Institute, Emory University, Atlanta, Georgia, United States
🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

and more 64 locations

Trial to Investigate the Safety and Efficacy of GWP42003-P Versus Placebo as Adjunctive Therapy in Participants With Schizophrenia Experiencing Inadequate Response to Ongoing Antipsychotic Treatment

Phase 2

Terminated

Conditions: Schizophrenia

Interventions: Drug: GWP42003-P
Drug: Placebo

First Posted Date: 2020-06-09

Last Posted Date: 2023-06-15

Lead Sponsor: Jazz Pharmaceuticals

Target Recruit Count: 95

Registration Number: NCT04421456

Locations: 🇪🇸
Clinical Trial Site, Valladolid, Spain
🇷🇸
Clinical Trial Site#1, Kragujevac, Serbia
🇷🇸
Clinical Trial Site#2, Kragujevac, Serbia

and more 1 locations

A Multicenter Expanded Access Treatment Protocol of Lurbinectedin in Previously Treated SCLC in the USA

Conditions: Small Cell Lung Cancer

First Posted Date: 2020-03-02

Last Posted Date: 2020-06-19

Lead Sponsor: Jazz Pharmaceuticals

Registration Number: NCT04291937

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy